Article
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.
The oncologist - 1 Jan 2012
Chen Zhi-Yong, Zhong Wen-Zhao, Zhang Xu-Chao, Su Jian, Yang Xue-Ning, Chen Zhi-Hong, Yang Jin-Ji, Zhou Qing, Yan Hong-Hong, An She-Juan, Chen Hua-Jun, Jiang Ben-Yuan, Mok Tony S, Wu Yi-Long
Abstract excerpt
BACKGROUND: Non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor heterogeneity in EGFR mutations is one potential explanation for this phenomenon. METHODS: We performed direct sequencing to identify EGFR mutations in 180 pairs of lung adenocarcinoma samples (from 3,071 patients). The high-resolution melting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.